Repligen raises $1.0bn in 0.25% convertibles to refinance debt due 2028

Some $458.6m of the new notes will be sold for cash and $541.4m swapped for older 1.00% paper, with $120.0m of the proceeds going to a share buyback at $188.64.

Repligen is pushing its nearest convertible debt out by three years and paying far less for it. The company will issue $1.0bn of 0.25% convertible notes due 2031, replacing paper that carries a 1.00% coupon and falls due in 2028.

The deal has two halves. Holders of about $456.8m of the 2028 notes will swap them for $541.4m of the new notes, leaving roughly $143.2m of the old issue outstanding. The other $458.6m will be sold for cash. Closing is expected on or about November 6.

The exchange is the part that matters. Moving roughly $457m of debt from a 1.00% coupon to 0.25% lowers annual interest costs, and it takes a maturity off the near-term calendar. That helps while Repligen is still absorbing the BioLife Solutions acquisition, which closed earlier this month and has left the balance sheet carrying acquisition-related costs. The cash raised adds fresh capital on top.

Convertibles carry a price, though: the conversion feature can dilute existing shareholders. Repligen plans to use about $120.0m of the cash proceeds to buy back shares at $188.64 each, which is meant to offset that dilution and to help the transactions go through.

The timing looks deliberate. Repligen is due to explain BioLife's effect on its 2026 guidance on its third-quarter call, and management has dealt with the financing before investors get a first look at the combined company's economics. The call can then be about the business, not the debt.